ACAbhishek Chaturvedi

Abhishek Chaturvedi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abhishek Chaturvedi has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Noninvasive Wearable-Based Algorithm to Predict Worsening Heart Failure by Change in Natriuretic Peptide Levels

    by Abhishek Chaturvedi, Savitesh Kushwaha, Uday K. Dixit, Arun Pulikkottil Jose, Rohan Goswami, Shunsuke Matsuoka, Sidhant Jena, Dipti Itchhaporia, Andrew J. Sauer, Dorairaj Prabhakaran, et al.

  • Progression of Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Replacement: A Quantitative Coronary Angiography and Quantitative Flow Ratio Analysis

    by Jason Galo, Abdullah Al Qaraghuli, Cheng Zhang, Gal Peleg, Kalyan R. Chitturi, Yonathan Hasin, Idit Avrahami, Shaan A. Ahmed, Pablo M. Rubio, Abhishek Chaturvedi, et al.

    Background: The progression of coronary artery disease (CAD) following transcatheter aortic valve replacement (TAVR) is poorly understood. Changes in coronary hemodynamics after TAVR and their relationship with atherosclerosis remain an active area of investigation. Quantitative coronary angiography (QCA) and quantitative flow ratio (QFR) offer objective, reproducible assessments of coronary disease burden, hemodynamics, and progression. Aims: To evaluate anatomic and hemodynamic progression of CAD in select patients undergoing TAVR using QCA and QFR, and to compare outcomes by valve type—self‐expanding valves (SEV) versus balloon‐expandable valves (BEV). Methods: A total of 92 patients who underwent TAVR and had both pre‐ and post‐TAVR invasive coronary angiography (CA) were retrospectively analyzed. QCA and QFR analyses were performed on major coronary arteries. CAD progression was defined in 2 ways: (1) QCA diameter stenosis (DS) increase ≥ 10% or baseline < 50% and follow‑up ≥ 50%; (2) QFR decrease ≥ 0.05 or baseline QFR > 0.80 and follow‐up ≤ 0.80. Clinical and echocardiographic data, statin use, and antiplatelet therapy were assessed longitudinally. Results: Over a median follow‐up of 756 days (IQR 254–1302), CAD progression in patients with clinically indicated post‐TAVR CA was observed in 96.6% of patients using QCA and in 85.6% of patients using QFR. Among vessel subsegments, CAD progression by QCA was greatest in the LAD proximal and mid segments (60.99% and 58.46%, respectively), and lowest in distal LCX and distal RCA (37.63%, 39.04%, respectively). CAD progression by QFR was significantly greater in SEV when compared to BEV (1‐year: 39.4% vs. 21.9%; 2‐year: 47.4% vs. 39.3%, log rank p  = 0.038). There was no statistically significant difference in the QCA‐defined CAD progression between SEV and BEV, though a numerically higher progression was seen in SEV. Conclusions: Most TAVR recipients undergoing clinically indicated repeat CA demonstrate CAD progression on serial angiography. By QFR, progression is influenced by valve type, while by QCA and QFR, trended with baseline disease severity. Further investigation into coronary progression following TAVR is warranted.


  • Low‐ Versus High‐capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis

    by Dan Haberman, Beni Verma, Waiel Abusnina, Jason Galo, Kalyan R. Chitturi, Lior Lupu, Matteo Cellamare, Cheng Zhang, Abhishek Chaturvedi, Mohammad Salman Khalil, et al.

    Background: Acute myocardial infarction with cardiogenic shock (AMI‐CS) remains highly fatal despite advances in revascularization and intensive care. The Impella, a micro‐axial pump, offers a potential balance of hemodynamic support and minimal invasiveness. Aims: This study examined its optimal configuration of low‐ versus high‐capacity for effectiveness and safety. Methods: We conducted a systematic review and pooled analysis of 20 studies, including three randomized controlled trials (RCTs) and 3896 AMI‐CS patients, comparing high‐capacity (Impella 5.0/5.5) versus low‐capacity (Impella 2.5/CP) devices. The primary outcome was in‐hospital or 30‐day mortality, with secondary endpoints including mortality on support, ischemic and bleeding complications, acute kidney injury requiring renal replacement therapy (RRT), and hemolysis. Results: Among the included patients, 2022 received low‐capacity Impella, while 771 received high‐capacity Impella. The high‐capacity Impella group demonstrated lower in‐hospital or 30‐day mortality (41.4% vs. 45.4%; p = 0.045) and significantly reduced mortality on support (17.9% vs. 46.1%; p < 0.001). Major bleeding events (1.4% vs. 6.0%; p < 0.001) and ischemic complications (3.9% vs. 5.9%; p = 0.05) were also lower in the high‐capacity group. However, transfusion requirements were higher in the high‐capacity Impella cohort (52.1% vs. 23.1%; p < 0.001). There were no significant differences in stroke rates (4.3% vs. 4.3%; p = 1.0) or AKI requiring RRT (36.5% vs. 34.9%; p = 0.69). Conclusion: High‐capacity Impella, when compared to low‐capacity devices, may provide superior survival benefits and lower complication rates, particularly in reducing ischemic and major bleeding events, in AMI‐CS patients. These findings support the early consideration of high‐capacity Impella in treatment algorithms.


  • Open Access

    Use of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting

    by Jennifer A. Rymer, Courtney Page, Brooke Alhanti, Cayla Pichan, Aman Kansal, Deepak L. Bhatt, Ajar Kochar, Dominick J. Angiolillo, Miguel Diaz, Neil J. Wimmer, et al.


  • Comparative Visual Analysis of Coronary Slow Flow and Myocardial Blush Grade in Relation to Invasive Testing for Coronary Microvascular Dysfunction

    by Andrew P. Hill, Ryan L. Wallace, Abhishek Chaturvedi, Flavia Tejada Frisancho, Matteo Cellamare, Vaishnavi Sawant, Sevket Ozturk, Vijoli Cermak, Cheng Zhang, Ron Waksman, et al.

    Background: Angiographic coronary slow flow (CSF) has been correlated with coronary microvascular dysfunction (CMD) and abnormal myocardial blush grade (MBG) has been associated with worse outcomes in acute myocardial infarction. Their validity has not been compared with newer invasive forms of coronary functional CMD testing. Therefore, we aimed to investigate whether angiographic assessment of CSF and MBG correlate with gold‐standard invasive assessments of CMD. Methods: Using the Coronary Microvascular Disease Registry (NCT05960474), we identified patients with angina and non‐obstructive coronary arteries (ANOCA) who underwent invasive coronary functional testing (CFT) between August 2021 and August 2024. CMD was defined as coronary flow reserve (CFR) < 2.5 with an index of microcirculatory resistance (IMR) > 25 using invasive bolus thermodilution technique. CSF was defined as > 3 cardiac cycles for distal opacification of vessels with contrast. Slow Thrombolysis in Myocardial Infarction frame count (TFC) was defined as a corrected frame count of > 25. MBG was categorized as abnormal (Grade 0 or 1). Rates of abnormal CSF and MBG were compared between the CMD‐positive and negative groups. Results: A total of 304 patients were included, of whom 81 (26.6%) were CMD positive. Patients were predominantly female (67.9 vs. 63.7%, p = 0.50) and slightly older (64.0 ± 11.3 vs. 60.6 ± 10.8 years, p = 0.02) with a lower BMI (28.5 ± 5.7 vs. 31.6 ± 6.9; p < 0.001) in the CMD positive group. Common comorbidities included hypertension, hyperlipidemia, and diabetes with a similar prevalence in both groups. There was no difference between CMD‐positive and negative groups for CSF, (8.6% vs. 4.9%, p = 0.23) or slow cTFC (14.8% vs. 15.7%, p = 0.85). Additionally, the rate of abnormal MBG was similar in both groups (1.3% vs. 3.1%; p = 0.37). Conclusion: Our findings suggest that, while readily available and previously used for diagnosis, the angiographic findings of CSF and MBG do not reliably indicate the presence of CMD in ANOCA patients. Therefore, dedicated CFT should be pursued if there is clinical suspicion of CMD.


  • Hemodynamic Evaluation of Concomitant Aortic Stenosis and Hypertrophic Obstructive Cardiomyopathy With Pressure Wire

    by Dan Haberman, Abhishek Chaturvedi, Lior Lupu, Kalyan R. Chitturi, Waiel Abusnina, Toby Rogers, Lowell Satler, Ron Waksman, Itsik Ben‐Dor

    Concomitant aortic stenosis (AS) and hypertrophic obstructive cardiomyopathy (HOCM) pose significant diagnostic and therapeutic challenges due to overlapping hemodynamic features. We present a case of an 89‐year‐old woman with severe AS and suspected LVOT obstruction, where imaging modalities were inconclusive. Invasive hemodynamic assessment using a pressure wire enabled precise differentiation and quantification of AS and LVOT gradients, including response to premature ventricular contractions. Based on these findings, alcohol septal ablation was performed before transcatheter aortic valve replacement (TAVR), resulting in improved hemodynamics and enabling safe TAVR. This case highlights the clinical value of pressure wire techniques for refined hemodynamic assessment and procedural planning in patients with dual pathology.

  • Optimizing MANTA Closure and Bailout in Large‐Bore Femoral Access: Computed Tomography Angiography‐Derived Measurements and Rescue Strategies

    by Lior Lupu, Andrew P. Hill, Dan Haberman, Kalyan R. Chitturi, Matteo Cellamare, Cheng Zhang, Vaishnavi Sawant, Waiel Abusnina, Abhishek Chaturvedi, Lowell F. Satler, et al.

    Background: The MANTA (Teleflex, Wayne, PA, USA) facilitates hemostasis in large‐bore femoral access. However, precise measurement of the common femoral artery depth is required before arteriotomy upsizing. This measurement may be unavailable in emergencies or bailout scenarios for suture‐based closures. Aims: This study aimed to evaluate computed tomography (CT) angiography‐derived common femoral artery depth measurement as an alternative to the MANTA Depth Locator. Methods: This retrospective study at MedStar Washington Hospital Center included all patients with available preprocedural ilio‐femoral CT angiography undergoing transfemoral aortic valve reintervention from March 13, 2023, to September 4, 2024. CT measurements of skin‐to‐artery depth at a designated puncture site, based on the MANTA Instructions for Use 45‐degree approach, were compared with intraprocedural MANTA Depth Locator measurements. The acceptable threshold for agreement was defined as ±2 cm to ensure safe in‐vessel deployment. Results: Among 289 patients (mean age 78.2 years, 43.6% female), 91% of CT‐derived measurements fell within the 2 cm threshold, demonstrating strong agreement. Logistic regression showed that a higher BMI reduced accuracy, with each unit increase in BMI decreasing the odds of meeting the threshold by 11% (OR 0.89; p < 0.001). For patients with BMI ≤ 30 kg/m 2 ( n = 189), the agreement increased to 96%. Conclusions: CT angiography‐derived measurements align well with MANTA Depth Locator measurements, although accuracy declines with increasing BMI. These findings support CT imaging as a reliable alternative to MANTA bailout in large‐bore access procedures. A practical algorithm for MANTA bailout techniques is proposed to guide clinical practice.

  • A Systematic Approach and Practical Guide to Using Bolus Thermodilution for Invasive Coronary Microvascular Dysfunction Assessment

    by Jason Galo, Abhishek Chaturvedi, Beni Rai Verma, Kalyan R. Chitturi, Haberman Dan, Waiel Abusnina, Itsik Ben‐Dor, Ron Waksman, Brian C. Case, Hayder D. Hashim

    Angina pectoris with non‐obstructive coronary arteries (ANOCA) is a prevalent condition, particularly affecting women, and is often associated with coronary microvascular dysfunction (CMD). CMD, the primary cause of ANOCA, is associated with a diminished quality of life and adverse clinical outcomes. Invasive coronary function testing (CFT) now provides a precise diagnosis of CMD through indices such as coronary flow reserve (CFR) and index of microcirculatory resistance (IMR), assessed using the bolus thermodilution technique. This comprehensive review outlines a systematic approach to evaluating CMD, emphasizing practical steps and troubleshooting strategies to ensure accurate measurements of CFR and IMR. CMD phenotypes, including structural, functional, and compensated CMD, are discussed, along with their distinct pathophysiological mechanisms. Common challenges encountered during CMD testing, such as improper guide or wire positioning, waveform artifacts, and injection errors, are addressed with practical solutions. While continuous thermodilution offers enhanced accuracy, bolus thermodilution remains cost‐effective and widely utilized. Proficiency in the intricacies of CMD testing is crucial for accurate diagnosis and management, ultimately enhancing clinical outcomes for this underrecognized patient population.


  • Open Access

    Epicardial Fat Tissue: A Potential Marker for Coronary Microvascular Dysfunction

    by Waiel Abusnina, Ilan Merdler, Matteo Cellamare, Kalyan R. Chitturi, Abhishek Chaturvedi, Irwin M. Feuerstein, Cheng Zhang, Sevket Tolga Ozturk, Teshome Deksissa, Vaishnavi Sawant, et al.

    Background: Coronary microvascular dysfunction (CMD), which mimics symptoms of obstructive coronary artery disease, has significant prognostic implications. While epicardial adipose tissue normally has a protective role, increased epicardial adipose tissue is associated with inflammation and may contribute to CMD. However, a direct correlation remains unclear. We aimed to investigate this association. Methods and Results: The CMDR (Coronary Microvascular Disease Registry) is a prospective, 2‐center registry that is enrolling patients with angina and nonobstructive coronary artery disease who underwent invasive hemodynamic assessment of the coronary microvasculature. Patients with chest computed tomography within 1 year of CMD evaluation were included. We measured epicardial fat volume (EFV) and calculated the EFV index. Logistic regression analysis was used to investigate the association between EFV and EFV index to CMD. Our study included 130 CMDR patients with associated chest CT; 35 were diagnosed with CMD. The CMD‐negative patients were younger than the CMD‐positive patients (58.52±11.97 versus 63.37±9.56 years; P =0.033), with numerically fewer women (64.2% versus 74.3%; P =0.279). Univariate regression analysis demonstrated a statistically significant association between EFV index and CMD diagnosis (odds ratio, 1.037 [95% CI, 1.014–1.063]; P =0.003), while no significance was observed for EFV (odds ratio, 1.006 [95% CI, 0.995–1.017]; P =0.292). Conclusions: Our results suggest a strong association between EFV index (a significant risk factor) and the presence of CMD. Future studies involving larger cohorts are needed to confirm the association of epicardial adipose tissue with CMD and investigate therapeutic targets to prevent CMD. Registration: URL: https://www.clinicaltrials.gov ; unique identifier: NCT05960474.